US 12,252,556 B2
Cyclosporine compositions and methods of use
Chris Murphy, Upton, MA (US); Ronald Farquhar, Boston, MA (US); and Roland E. Dolle, Eureka, MO (US)
Assigned to BACAINN BIOTHERAPEUTICS, LTD., George Town (KY)
Appl. No. 17/269,614
Filed by Bacainn Biotherapeutics, Ltd., George Town, KY (US)
PCT Filed Aug. 20, 2019, PCT No. PCT/US2019/047354
§ 371(c)(1), (2) Date Feb. 19, 2021,
PCT Pub. No. WO2020/041378, PCT Pub. Date Feb. 27, 2020.
Claims priority of provisional application 62/721,195, filed on Aug. 22, 2018.
Prior Publication US 2021/0277064 A1, Sep. 9, 2021
Int. Cl. C07K 7/64 (2006.01); A61K 45/06 (2006.01); A61K 47/60 (2017.01)
CPC C07K 7/645 (2013.01) [A61K 45/06 (2013.01); A61K 47/60 (2017.08)] 23 Claims
 
1. A compound having the structure of Formula I,

OG Complex Work Unit Chemistry
a stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing;
wherein
L1 is a C1 to C4 alkyl group optionally substituted with one or more F;
R is a PEG having from 40 to 50 ethylene oxide units, wherein the PEG comprises a linker group, L2; and
L2 is a C1-6 unsubstituted heteroalkylene having one or two nitrogen atoms.